Compile Data Set for Download or QSAR
maximum 50k data
Found 157 Enz. Inhib. hit(s) with all data for entry = 9202
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448845(US10696672, Compound 77 | US11634418, Compound 77)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448846(US10696672, Compound 78 | US11634418, Compound 78)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448847(US10696672, Compound 79 | US11634418, Compound 79)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448848(US10696672, Compound 80 | US11634418, Compound 80)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448850(US10696672, Compound 82 | US11634418, Compound 82)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448851(US10696672, Compound 83 | US11634418, Compound 83)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448852(US10696672, Compound 84 | US11634418, Compound 84)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448853(US10696672, Compound 85 | US11634418, Compound 85)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448854(US10696672, Compound 86 | US11634418, Compound 86)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448855(US10696672, Compound 87 | US11634418, Compound 87)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448856(US10696672, Compound 88 | US11634418, Compound 88)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448857(US10696672, Compound 89 | US11634418, Compound 89)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448858(US10696672, Compound 90 | US11634418, Compound 90)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448860(US10696672, Compound 92 | US11634418, Compound 92)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448863(US10696672, Compound 95 | US11634418, Compound 95)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448867(US10696672, Compound 99 | US11634418, Compound 99)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448871(US10696672, Compound 103 | US11634418, Compound 10...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448872(US10696672, Compound 104 | US11634418, Compound 10...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448878(US10696672, Compound 110 | US11634418, Compound 11...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448883(US10696672, Compound 115 | US11634418, Compound 11...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448891(US10696672, Compound 123 | US11634418, Compound 12...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448895(US10696672, Compound 127 | US11634418, Compound 12...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448908(US10696672, Compound 140 | US10696672, Compound 14...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448914(US10696672, Compound 146 | US11634418, Compound 14...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448736((R)-2-pivalamido-4-((R)-3-(2-(5,6,7,8- | US1069667...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448743((S)-2-((tert-butoxycarbonyl)amino)-4- | US10696672...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448745((S)-2-benzamido-4-((R)-3-(2-(5,6,7,8- | US10696672...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448745((S)-2-benzamido-4-((R)-3-(2-(5,6,7,8- | US10696672...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448757((S)-2-(2,6-dimethylbenzamido)-4-((R)- | US10696672...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448759((R)-2-(2,6-dimethylbenzamido)-4-((R)- | US10696672...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448760((S)-2-(2-chloro-3-fluorobenzamido)-4- | US10696672...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448761((S)-2-(2,6-dichlorobenzamido)-4-((R)- | US10696672...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448766(US10696672, Compound 7a | US11634418, Compound 7a)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448767(US10696672, Compound 7c | US11634418, Compound 7c)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448768((S)-4-((R)-3-(2-(5,6,7,8-tetrahydro-1,8- | US10696...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448771((S)-4-((R)-3-(2-(5,6,7,8-tetrahydro-1,8- | US10696...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448772((S)-4-((R)-3-(2-(5,6,7,8-tetrahydro-1,8- | US10696...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448774((S)-2-(2,6-dichlorobenzamido)-4-((R)- | US10696672...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448776((S)-2-(3-(3,5-dimethyl-1H-pyrazol-1- | US10696672,...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448777((R)-2-(3-(3,5-dimethyl-1H-pyrazol-1- | US10696672,...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448776((S)-2-(3-(3,5-dimethyl-1H-pyrazol-1- | US10696672,...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448777((R)-2-(3-(3,5-dimethyl-1H-pyrazol-1- | US10696672,...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448779((S)-2-(3-morpholinobenzamido)-4- | US10696672, Com...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448782((S)-2-(isonicotinamido)-4-((R)-3-(2- | US10696672,...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448784((S)-2-(3,5-dichloroisonicotinamido)-4- | US1069667...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448785((R)-2-(3,5-dichloroisonicotinamido)-4- | US1069667...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448786((S)-2-(4,4-difluorocyclohexane-1- | US10696672, Co...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448787((R)-2-(4,4-difluorocyclohexane-1- | US10696672, Co...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448791((S)-2-(1-methyl-1H-indazole-6- | US10696672, Compo...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-6(Homo sapiens (Human))
Pliant Therapeutics

US Patent
LigandPNGBDBM448793((S)-2-(1H-indazole-7-carboxamido)-4- | US10696672,...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 157 total ) | Next | Last >>
Jump to: